Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK PSO-1 and PSO-2 trials

N/A

Saved in:
Bibliographic Details
Published inSkin (Milwood, N.Y.) Vol. 6; no. 6; p. s49
Main Authors Blauvelt, Andrew, Rich, Phoebe, Sofen, Howard, Lambert, Jo, Merola, Joseph F, Lebwohl, Mark, Scharnitz, Thomas, Hoyt, Kim, Kisa, Renata M, Banerjee, Subhashis
Format Journal Article
LanguageEnglish
Published 16.11.2022
Online AccessGet full text

Cover

More Information
Summary:N/A
ISSN:2574-1624
2574-1624
DOI:10.25251/skin.6.supp.49